Jinjing Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinjing Yao has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Sui Rong Wayne Chen
Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB T2N 4Z6, Canada
10 shared publications Bo Sun
Medical School, Kunming University of Science and Technology, Kunming, China
6 shared publicationsJohn Paul Estillore
Libin Cardiovascular Institute, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB T2N 4N1, Canada
5 shared publicationsRuiwu Wang
Libin Cardiovascular Institute, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB T2N 4N1, Canada
4 shared publicationsThomas G. Back
Department of Chemistry, University of Calgary, Calgary, AB T2N 1N4, Canada
4 shared publications- Mingke Ni
Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, Canada (B.S., M. Ni, Y.L., Z.S., H.W., H.-L.Z., J.W., D.B., S.C., W.G., J.Y., S.T., J.P.E., R.W., S.R.W.C.).
3 shared publications
Latest Publications
- Open Access
- 25 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (12) , 847-862
Inositol 1,4,5-Trisphosphate Receptor 1 Gain-of-Function Increases the Risk for Cardiac Arrhythmias in Mice and Humans
BACKGROUND: Ca 2+ mishandling in cardiac Purkinje cells is a well-known cause of cardiac arrhythmias. The Purkinje cell resident inositol 1,4,5-trisphosphate receptor 1 (ITPR1) is believed to play an important role in Ca 2+ handling, and ITPR1 gain-of-function (GOF) has been implicated in cardiac arrhythmias. However, nearly all known disease-associated ITPR1 variants are loss-of-function and are primarily linked to neurological disorders. Whether ITPR1 GOF has pathological consequences, such as cardiac arrhythmias, is unclear. This study aimed to identify human ITPR1 GOF variants and determine the impact of ITPR1 GOF on Ca 2+ handling and arrhythmia susceptibility. METHODS: There are a large number of rare ITPR1 missense variants reported in open data repositories. Based on their locations in the ITPR1 channel structure, we selected and characterized 33 human ITPR1 missense variants from open databases and identified 21 human ITPR1 GOF variants. We generated a mouse model carrying a human ITPR1 GOF variant, ITPR1-W1457G (W1447G in mice). RESULTS: We showed that the ITPR1-W1447G +/- and recently reported ITPR1-D2594K +/- GOF mutant mice were susceptible to stress-induced ventricular arrhythmias. Confocal Ca 2+ and voltage imaging in situ in heart slices and Ca 2+ imaging and patch-clamp recordings of isolated Purkinje cells showed that ITPR1-W1447G +/- and ITPR1-D2594K +/- variants increased the occurrence of stress-induced spontaneous Ca 2+ release, delayed afterdepolarization, and triggered activity in Purkinje cells. To assess the potential role of ITPR1 variants in arrhythmia susceptibility in humans, we looked up a gene-based association study in the UK Biobank data set and identified 7 rare ITPR1 missense variants showing potential association with cardiac arrhythmias. Remarkably, in vitro functional characterization revealed that all these 7 ITPR1 variants resulted in GOF. CONCLUSIONS: Our studies in mice and humans reveal that enhanced function of ITPR1 , a well-known movement disorder gene, increases the risk for cardiac arrhythmias.
- 25 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (12) , 847-862
Open AccessInositol 1,4,5-Trisphosphate Receptor 1 Gain-of-Function Increases the Risk for Cardiac Arrhythmias in Mice and Humans
BACKGROUND: Ca 2+ mishandling in cardiac Purkinje cells is a well-known cause of cardiac arrhythmias. The Purkinje cell resident inositol 1,4,5-trisphosphate receptor 1 (ITPR1) is believed to play an important role in Ca 2+ handling, and ITPR1 gain-of-function (GOF) has been implicated in cardiac arrhythmias. However, nearly all known disease-associated ITPR1 variants are loss-of-function and are primarily linked to neurological disorders. Whether ITPR1 GOF has pathological consequences, such as cardiac arrhythmias, is unclear. This study aimed to identify human ITPR1 GOF variants and determine the impact of ITPR1 GOF on Ca 2+ handling and arrhythmia susceptibility. METHODS: There are a large number of rare ITPR1 missense variants reported in open data repositories. Based on their locations in the ITPR1 channel structure, we selected and characterized 33 human ITPR1 missense variants from open databases and identified 21 human ITPR1 GOF variants. We generated a mouse model carrying a human ITPR1 GOF variant, ITPR1-W1457G (W1447G in mice). RESULTS: We showed that the ITPR1-W1447G +/- and recently reported ITPR1-D2594K +/- GOF mutant mice were susceptible to stress-induced ventricular arrhythmias. Confocal Ca 2+ and voltage imaging in situ in heart slices and Ca 2+ imaging and patch-clamp recordings of isolated Purkinje cells showed that ITPR1-W1447G +/- and ITPR1-D2594K +/- variants increased the occurrence of stress-induced spontaneous Ca 2+ release, delayed afterdepolarization, and triggered activity in Purkinje cells. To assess the potential role of ITPR1 variants in arrhythmia susceptibility in humans, we looked up a gene-based association study in the UK Biobank data set and identified 7 rare ITPR1 missense variants showing potential association with cardiac arrhythmias. Remarkably, in vitro functional characterization revealed that all these 7 ITPR1 variants resulted in GOF. CONCLUSIONS: Our studies in mice and humans reveal that enhanced function of ITPR1 , a well-known movement disorder gene, increases the risk for cardiac arrhythmias.
- 8 May 2023
- Published by Elsevier in Neuroscience
- Vol. 522, 11-22
A Gain-of-function Mutation in the Gating Domain of ITPR1 Impairs Motor Movement and Increases Thermal and Mechanical Sensitivity
- 8 May 2023
- Published by Elsevier in Neuroscience
- Vol. 522, 11-22
A Gain-of-function Mutation in the Gating Domain of ITPR1 Impairs Motor Movement and Increases Thermal and Mechanical Sensitivity
- Open Access
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1125890
Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease
Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1125890
Open AccessCorrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease
Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease
- Open Access
- 24 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1062495
R-carvedilol, a potential new therapy for Alzheimer’s disease
For decades, the amyloid cascade hypothesis has been the leading hypothesis in studying Alzheimer’s disease (AD) pathology and drug development. However, a growing body of evidence indicates that simply removing amyloid plaques may not significantly affect AD progression. Alternatively, it has been proposed that AD progression is driven by increased neuronal excitability. Consistent with this alternative hypothesis, recent studies showed that pharmacologically limiting ryanodine receptor 2 (RyR2) open time with the R-carvedilol enantiomer prevented and reversed neuronal hyperactivity, memory impairment, and neuron loss in AD mouse models without affecting the accumulation of ß-amyloid (Aβ). These data indicate that R-carvedilol could be a potential new therapy for AD.
- 24 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1062495
Open AccessR-carvedilol, a potential new therapy for Alzheimer’s disease
For decades, the amyloid cascade hypothesis has been the leading hypothesis in studying Alzheimer’s disease (AD) pathology and drug development. However, a growing body of evidence indicates that simply removing amyloid plaques may not significantly affect AD progression. Alternatively, it has been proposed that AD progression is driven by increased neuronal excitability. Consistent with this alternative hypothesis, recent studies showed that pharmacologically limiting ryanodine receptor 2 (RyR2) open time with the R-carvedilol enantiomer prevented and reversed neuronal hyperactivity, memory impairment, and neuron loss in AD mouse models without affecting the accumulation of ß-amyloid (Aβ). These data indicate that R-carvedilol could be a potential new therapy for AD.
- Open Access
- 1 March 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-16
Subcellular localization of hippocampal ryanodine receptor 2 and its role in neuronal excitability and memory
Ryanodine receptor 2 (RyR2) is abundantly expressed in the heart and brain. Mutations in RyR2 are associated with both cardiac arrhythmias and intellectual disability. While the mechanisms of RyR2-linked arrhythmias are well characterized, little is known about the mechanism underlying RyR2-associated intellectual disability. Here, we employed a mouse model expressing a green fluorescent protein (GFP)-tagged RyR2 and a specific GFP probe to determine the subcellular localization of RyR2 in hippocampus. GFP-RyR2 was predominantly detected in the soma and dendrites, but not the dendritic spines of CA1 pyramidal neurons or dentate gyrus granular neurons. GFP-RyR2 was also detected within the mossy fibers in the stratum lucidum of CA3, but not in the presynaptic terminals of CA1 neurons. An arrhythmogenic RyR2-R4496C+/− mutation downregulated the A-type K+ current and increased membrane excitability, but had little effect on the afterhyperpolarization current or presynaptic facilitation of CA1 neurons. The RyR2-R4496C+/− mutation also impaired hippocampal long-term potentiation, learning, and memory. These data reveal the precise subcellular distribution of hippocampal RyR2 and its important role in neuronal excitability, learning, and memory.
- 1 March 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-16
Open AccessSubcellular localization of hippocampal ryanodine receptor 2 and its role in neuronal excitability and memory
Ryanodine receptor 2 (RyR2) is abundantly expressed in the heart and brain. Mutations in RyR2 are associated with both cardiac arrhythmias and intellectual disability. While the mechanisms of RyR2-linked arrhythmias are well characterized, little is known about the mechanism underlying RyR2-associated intellectual disability. Here, we employed a mouse model expressing a green fluorescent protein (GFP)-tagged RyR2 and a specific GFP probe to determine the subcellular localization of RyR2 in hippocampus. GFP-RyR2 was predominantly detected in the soma and dendrites, but not the dendritic spines of CA1 pyramidal neurons or dentate gyrus granular neurons. GFP-RyR2 was also detected within the mossy fibers in the stratum lucidum of CA3, but not in the presynaptic terminals of CA1 neurons. An arrhythmogenic RyR2-R4496C+/− mutation downregulated the A-type K+ current and increased membrane excitability, but had little effect on the afterhyperpolarization current or presynaptic facilitation of CA1 neurons. The RyR2-R4496C+/− mutation also impaired hippocampal long-term potentiation, learning, and memory. These data reveal the precise subcellular distribution of hippocampal RyR2 and its important role in neuronal excitability, learning, and memory.
- 5 January 2022
- Published by Wiley in Alzheimer's & Dementia
- Vol. 18 (11) , 2088-2098
Increased RyR2 open probability induces neuronal hyperactivity and memory loss with or without Alzheimer's disease–causing gene mutations
Introduction: Neuronal hyperactivity is an early neuronal defect commonly observed in familial and sporadic Alzheimer's disease (AD), but the underlying mechanisms are unclear.Methods: We employed a ryanodine receptor 2 (RyR2) mutant mouse model harboring the R4496C+/– mutation that markedly increases the channel's open probability (Po) to determine the impact of increased RyR2 activity in neuronal function without AD gene mutations.Results: Genetically increasing RyR2 Po induced neuronal hyperactivity in vivo in anesthetized and awake mice. Increased RyR2 Po induced hyperactive behaviors, impaired learning and memory, defective dendritic spines, and neuronal cell death. Increased RyR2 Po exacerbated the onset of neuronal hyperexcitability and learning and memory impairments in 5xFAD mice.Discussion: Increased RyR2 Po exacerbates the onset of familial AD–associated neuronal dysfunction, and induces AD‐like defects in the absence of AD‐causing gene mutations, suggesting that RyR2‐associated neuronal hyperactivity represents a common target for combating AD with or without AD gene mutations.
- 5 January 2022
- Published by Wiley in Alzheimer's & Dementia
- Vol. 18 (11) , 2088-2098
Increased RyR2 open probability induces neuronal hyperactivity and memory loss with or without Alzheimer's disease–causing gene mutations
Introduction: Neuronal hyperactivity is an early neuronal defect commonly observed in familial and sporadic Alzheimer's disease (AD), but the underlying mechanisms are unclear.Methods: We employed a ryanodine receptor 2 (RyR2) mutant mouse model harboring the R4496C+/– mutation that markedly increases the channel's open probability (Po) to determine the impact of increased RyR2 activity in neuronal function without AD gene mutations.Results: Genetically increasing RyR2 Po induced neuronal hyperactivity in vivo in anesthetized and awake mice. Increased RyR2 Po induced hyperactive behaviors, impaired learning and memory, defective dendritic spines, and neuronal cell death. Increased RyR2 Po exacerbated the onset of neuronal hyperexcitability and learning and memory impairments in 5xFAD mice.Discussion: Increased RyR2 Po exacerbates the onset of familial AD–associated neuronal dysfunction, and induces AD‐like defects in the absence of AD‐causing gene mutations, suggesting that RyR2‐associated neuronal hyperactivity represents a common target for combating AD with or without AD gene mutations.
- 5 August 2021
- Published by Wiley in Journal of Neuroscience Research
- Vol. 99 (11) , 2906-2921
Limiting RyR2 open time prevents Alzheimer's disease‐related deficits in the 3xTG‐AD mouse model
Increasing evidence suggests that Alzheimer's disease (AD) progression is driven by a vicious cycle of soluble β‐amyloid (Aβ)‐induced neuronal hyperactivity. Thus, breaking this vicious cycle by suppressing neuronal hyperactivity may represent a logical approach to stopping AD progression. In support of this, we have recently shown that genetically and pharmacologically limiting ryanodine receptor 2 (RyR2) open time prevented neuronal hyperactivity, memory impairment, dendritic spine loss, and neuronal cell death in a rapid, early onset AD mouse model (5xFAD). Here, we assessed the impact of limiting RyR2 open time on AD‐related deficits in a relatively late occurring, slow developing AD mouse model (3xTG‐AD) that bears more resemblance (compared to 5xFAD) to that of human AD. Using behavioral tests, long‐term potentiation recordings, and Golgi and Nissl staining, we found that the RyR2‐E4872Q mutation, which markedly shortens the open duration of the RyR2 channel, prevented learning and memory impairment, defective long‐term potentiation, dendritic spine loss, and neuronal cell death in the 3xTG‐AD mice. Furthermore, pharmacologically shortening the RyR2 open time with R‐carvedilol rescued these AD‐related deficits in 3xTG mice. Therefore, limiting RyR2 open time may offer a promising, neuronal hyperactivity‐targeted anti‐AD strategy.
- 5 August 2021
- Published by Wiley in Journal of Neuroscience Research
- Vol. 99 (11) , 2906-2921
Limiting RyR2 open time prevents Alzheimer's disease‐related deficits in the 3xTG‐AD mouse model
Increasing evidence suggests that Alzheimer's disease (AD) progression is driven by a vicious cycle of soluble β‐amyloid (Aβ)‐induced neuronal hyperactivity. Thus, breaking this vicious cycle by suppressing neuronal hyperactivity may represent a logical approach to stopping AD progression. In support of this, we have recently shown that genetically and pharmacologically limiting ryanodine receptor 2 (RyR2) open time prevented neuronal hyperactivity, memory impairment, dendritic spine loss, and neuronal cell death in a rapid, early onset AD mouse model (5xFAD). Here, we assessed the impact of limiting RyR2 open time on AD‐related deficits in a relatively late occurring, slow developing AD mouse model (3xTG‐AD) that bears more resemblance (compared to 5xFAD) to that of human AD. Using behavioral tests, long‐term potentiation recordings, and Golgi and Nissl staining, we found that the RyR2‐E4872Q mutation, which markedly shortens the open duration of the RyR2 channel, prevented learning and memory impairment, defective long‐term potentiation, dendritic spine loss, and neuronal cell death in the 3xTG‐AD mice. Furthermore, pharmacologically shortening the RyR2 open time with R‐carvedilol rescued these AD‐related deficits in 3xTG mice. Therefore, limiting RyR2 open time may offer a promising, neuronal hyperactivity‐targeted anti‐AD strategy.
- 1 July 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 758, 136011
Genetically and pharmacologically limiting RyR2 open time prevents neuronal hyperactivity of hippocampal CA1 neurons in brain slices of 5xFAD mice
- 1 July 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 758, 136011
Genetically and pharmacologically limiting RyR2 open time prevents neuronal hyperactivity of hippocampal CA1 neurons in brain slices of 5xFAD mice
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
Cardiac ryanodine receptor calcium release deficiency syndrome
Clinical and basic studies shed light on the mechanism, diagnosis, and treatment of cardiac ryanodine receptor Ca 2+ release deficiency syndrome.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
Cardiac ryanodine receptor calcium release deficiency syndrome
Clinical and basic studies shed light on the mechanism, diagnosis, and treatment of cardiac ryanodine receptor Ca 2+ release deficiency syndrome.
- Open Access
- 1 September 2020
- Published by Elsevier in Cell Reports
- Vol. 32 (12) , 108169
Limiting RyR2 Open Time Prevents Alzheimer’s Disease-Related Neuronal Hyperactivity and Memory Loss but Not β-Amyloid Accumulation
- 1 September 2020
- Published by Elsevier in Cell Reports
- Vol. 32 (12) , 108169
Open AccessLimiting RyR2 Open Time Prevents Alzheimer’s Disease-Related Neuronal Hyperactivity and Memory Loss but Not β-Amyloid Accumulation